Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Zevra Therapeutics (ZVRA)
NASDAQ:ZVRA
Holding ZVRA?
Track your performance easily
Earnings Data
Report Date
Feb 28, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.4Last Year’s EPS
-0.51Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 08, 2018
|% Change Since: -6.07%
|Next Earnings Date:Aug 09, 2018
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements with the approval and launch of MIPLYFFA, receiving a priority review voucher, and positive clinical pipeline developments. However, these were balanced by challenges with OLPRUVA's underperformance, increased expenses, and discontinued development activities.Company Guidance
During the earnings call, Zevra Therapeutics provided guidance on several key metrics. The launch of MIPLYFFA, the first FDA-approved therapy for Niemann-Pick disease type C, resulted in 90 prescription enrollment forms by the end of October, with 30% approved for reimbursement. The company expects MIPLYFFA to be available for patient shipment within 8 to 12 weeks post-launch. Meanwhile, OLPRUVA, intended for urea cycle disorders, underperformed with only three new prescription enrollments in Q3. Zevra aims to rectify this through targeted patient awareness strategies. Financially, Zevra reported $3.7 million in Q3 net revenue, mainly from French EAP reimbursements and royalties. With cash and investments totaling $95.5 million, the company anticipates its cash runway to extend into 2027. Additionally, Zevra plans to monetize a priority review voucher to support growth.Approval and Launch of MIPLYFFA
The first FDA-approved therapy for Niemann-Pick disease type C was launched, with 90 prescription enrollment forms submitted as of October 31.
Rare Pediatric Disease Priority Review Voucher
Received a priority review voucher with the approval of MIPLYFFA, intended to be monetized for future growth.
Clinical Pipeline Progress
Achieved end of Phase II meeting with the FDA for KP1077 in idiopathic hypersomnia and dosed new patients in Phase III program for celiprolol.
Strong Financial Position
Completed an underwritten public offering with net proceeds of approximately $64.5 million, extending cash runway into 2027.
---
ZVRA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ZVRA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $8.57 | $8.66 | +1.05% |
| Aug 13, 2024 | $6.78 | $6.99 | +3.10% |
| May 08, 2024 | $5.18 | $5.16 | -0.39% |
| Mar 28, 2024 | $5.80 | $5.16 | -11.03% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Zevra Therapeutics (ZVRA) report earnings?
Zevra Therapeutics (ZVRA) is schdueled to report earning on Feb 28, 2025, TBA Not Confirmed.
What is Zevra Therapeutics (ZVRA) earnings time?
Zevra Therapeutics (ZVRA) earnings time is at Feb 28, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ZVRA EPS forecast?
ZVRA EPS forecast for the fiscal quarter 2024 (Q4) is -0.4.
---